Given the highly varied expression levels of CHEK1 and BRD4 observed in the TCGA‐LIHC cohort, survival analyses were then performed to determine if the varied expression of CHEK1 and BRD4 conferred any survival benefit to HCC patients. Here, BRD4 is linked to hepatocellular carcinoma.